Peptides craze meets caution: unregulated injections spark safety and regulatory questions

A wellness-driven surge in peptide injections touted for healing, recovery, and muscle-building rests on limited clinical evidence and carries safety risks. In 2023 the FDA banned production of several peptides by compounding pharmacies due to safety concerns and impurities, and the agency does not approve such compounds. US policy discussions about legalizing broader compounding could boost access but also risk, as product quality and dosing vary and most data come from animal studies. Experts urge caution and emphasize that rigorous human trials are still needed to establish true benefits and safety.